Individual Response : Each patients body responds uniquely to Semaglutide GLP-1
For example, the SELECT trial revealed that patients on semaglutide maintained an average weight loss of -10.2% over four years (208 weeks), while the placebo group only saw a modest -1.5% reduction
Conclusion GLP-1 agonists have shown promise as effective treatments for obesity, especially in individuals who have not achieved sufficient weight loss with diet and exercise alone
Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss
Thats why Found provides a comprehensive set of prescription medications in addition to behavior change support and access to clinicians trained in obesity medicine
Patients should only use prescription medication, including any compounded medication, under the supervision of a qualified licensed clinician